SEARCH

Current Location: DOTmed News > Industry Headlines > This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

More Industry Headlines

Philips suspends CT and PET/CT production at Ohio facility Setback for customers and the company.

Varian's seven year patent dispute comes to an end Company will pay about $35 million.

FDA OKs GE's new CT scanner Ideal for challenging cases.

MRI technique can help treat concussion patients Measures white brain matter damage.

ABT's compact biomarker generator comes to Russia Ideal for the growing Russian market.

Special report: Contrast media One size does not fit all.

What's the big-picture impact of HIT on health care? Q&A with thought leader Bipin Thomas.

ClearMRI gets FDA clearance for MRI adaptor New option to extend the life of MRI systems.

Sebelius steps down from HHS post Sylvia Mathews Burwell to succeed Sebelius.

Physician payment data now available CMS releases records and AMA pushes back.

After ACA ruling, Medical device makers still hate the excise tax

by Brendon Nafziger , DOTmed News Associate Editor
Now that the Supreme Court has essentially upheld the Affordable Care Act, that means one really important thing to medical device companies: a 2.3 percent excise tax on device sales included in the bill will still take effect next year.

In a lighting-fast reaction to the news of the ACA's survival, Stephen Ubl, CEO of the Advanced Medical Technology Association, or AdvaMed, the device manufacturers trade lobby, issued a statement, saying his group would continue to work to squash the tax, which will raise nearly $29 billion over the next decade to help offset the costs of reform.

Story Continues Below Advertisement

Siemens Healthcare Customer Services Tip for Biomed Departments:

Know What You're Worth. Your department is a more visible part of the financial picture. Click here to estimate the revenue value of your department to help you manage your budget>>>



"AdvaMed supported goals of health care reform consistent with our long-held principles," Ubl said in the statement. But he said his group has opposed the excise tax because of "its damaging effects on economic competitiveness, jobs and the research and development needed to find tomorrow's treatments and cures."

Earlier this month, the House of Representatives, which Republicans control, voted to repeal the tax, but at the time the Senate, led by Democrats, said it wouldn't vote on the legislation. However, Ubl said in the news release that he was "heartened by the number of senators who have said they oppose the tax."

Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED